Premium
Up‐regulation of D 3 dopamine receptor mRNA by neuroleptics
Author(s) -
Wang Wei,
Hahn KyuHee,
Bishop John F.,
Gao DaQing,
Jose Pedro A.,
Mouradian M. Maral
Publication year - 1996
Publication title -
synapse
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.809
H-Index - 106
eISSN - 1098-2396
pISSN - 0887-4476
DOI - 10.1002/(sici)1098-2396(199607)23:3<232::aid-syn13>3.0.co;2-0
Subject(s) - dopamine receptor d3 , nucleus accumbens , haloperidol , sulpiride , olfactory tubercle , striatum , pimozide , dopamine receptor d2 , antipsychotic , dopamine receptor d1 , dopamine , dopamine receptor , medicine , pharmacology , clozapine , endocrinology , chemistry , schizophrenia (object oriented programming) , dopaminergic , psychiatry
The effects of 14 days neuroleptic treatment on the expression of the D 3 dopamine receptor gene was investigated in rats using a sensitive polymerase chain reaction assay. In olfactory tubercle, D 3 mRNA levels increased following haloperidol (40%), pimozide (56%), and sulpiride (63%) administration, and in nucleus accumbens, levels increased after haloperidol (50%) and sulpiride (50%). D 3 expression in the motor striatum did not change with any antagonist tested. Clozapine did not affect D 3 expression in any brain region. These data suggest that dopamine antagonists can regulate the expression of the D 3 receptor in a brain region selective manner. The findings also suggest that the motor complications of chronic antipsychotic therapy are not due to D 3 receptor up‐regulation in the striatum. (This article is a US Government work and, as such, is in the public domain in the United States of America.) © 1996 Wiley‐Liss, Inc.